Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 8 full-time employees. The company has filed a voluntary petition under chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the Southern District of New York.
Leveraging in-depth analyst evaluations, we have synthesized critical insights from expert assessments to deliver a robust outlook for SEELQ. Our analysts highlight strong fundamentals and favorable market sentiment, positioning SEELQ for significant upside potential in the near term. Based on this comprehensive expert analysis, we maintain a highly optimistic view of this stock. Our conclusion: SEELQ is a Strong Buy candidate.
SEELQ stock price ended at $0 on 水曜日, after rising NaN%
On the latest trading day Apr 22, 2026, the stock price of SEELQ rose by NaN%, climbing from $0.00 to $0.00. During the session, the stock saw a volatility of NaN%, with prices oscillating between a daily low of $0.00 and a high of $0.00. Notably, trading volume dropped by 99 shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 100 shares were traded, equating to a market value of approximately --.